703 filings
Page 5 of 36
8-K
VTGN
VistaGen Therapeutics Inc
7 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:40pm
S-3
VTGN
VistaGen Therapeutics Inc
Shelf registration
2 Mar 23
4:35pm
8-K
VTGN
VistaGen Therapeutics Inc
1 Mar 23
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
7:28pm
D
VTGN
VistaGen Therapeutics Inc
17 Feb 23
$2.80 mm in equity, 129 investors
6:24pm
SC 13G/A
VTGN
VistaGen Therapeutics Inc
14 Feb 23
VistaGen Therapeutics / ORBIMED ADVISORS ownership change
5:20pm
SC 13G/A
Commodore Capital LP
14 Feb 23
VistaGen Therapeutics / COMMODORE CAPITAL ownership change
4:06pm
SC 13G/A
Acuta Capital Partners, LLC
14 Feb 23
VistaGen Therapeutics / ACUTA CAPITAL PARTNERS ownership change
3:32pm
8-K
VTGN
VistaGen Therapeutics Inc
7 Feb 23
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
4:29pm
10-Q
2022 Q3
VTGN
VistaGen Therapeutics Inc
Quarterly report
7 Feb 23
4:16pm
8-K
VTGN
VistaGen Therapeutics Inc
2 Feb 23
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
9:10am
SC 13G/A
VTGN
VistaGen Therapeutics Inc
1 Feb 23
VistaGen Therapeutics / BlackRock ownership change
4:54pm
SC 13G/A
VTGN
VistaGen Therapeutics Inc
1 Feb 23
VistaGen Therapeutics / FRANKLIN RESOURCES ownership change
1:49pm
8-K
VTGN
VistaGen Therapeutics Inc
24 Jan 23
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
5:32pm
8-K
VTGN
VistaGen Therapeutics Inc
11 Jan 23
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
9:57pm
4
VTGN
VistaGen Therapeutics Inc
3 Jan 23
VistaGen Therapeutics / JERROLD DUANE DOTSON ownership change
4:11pm
4
Singh Shawn
3 Jan 23
VistaGen Therapeutics / Shawn Singh ownership change
4:10pm
8-K
VTGN
VistaGen Therapeutics Inc
21 Dec 22
Vistagen to Acquire Pherin Pharmaceuticals
8:30am
8-K
VTGN
VistaGen Therapeutics Inc
6 Dec 22
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
4:15pm
8-K
VTGN
VistaGen Therapeutics Inc
30 Nov 22
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
8:28pm
8-K
VTGN
VistaGen Therapeutics Inc
22 Nov 22
Regulation FD Disclosure
8:00pm